Clinical Trial Update: Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety, tolerability, and immunogenicity of two doses of an adjuvanted monovalent influenza vaccine in healthy adults and elderl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• Adjuvanted Monovalent Influenza Vaccine

Snippet

Sponsor: Novartis | Conditions: Pandemic Influenza Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-01-18